Further processing options
Radiosensitization of androgen receptor (AR)-positive triple-negative breast cancer (TNBC) cells using seviteronel (SEVI), a selective CYP17 lyase and AR inhibitor.
Saved in:
Journal Title: | Journal of Clinical Oncology |
---|---|
Authors and Corporations: | , , , , , , , , , , , , |
In: | Journal of Clinical Oncology, 35, 2017, 15_suppl, p. e12102-e12102 |
Type of Resource: | E-Article |
Language: | English |
published: |
American Society of Clinical Oncology (ASCO)
|
Subjects: |